DBVT

Announcements

Nothing here yet

Daily updates

• DBV Technologies submitted a BLA to the FDA for VIASKIN Peanut in children aged 4 to 7 with peanut allergy, supported by results from the 654-patient Phase 3 VITESSE study.Sep 30, 2026

FDA designations

Nothing here yet

News

• DBV Technologies screened the first participant in the THRIVE Phase 2 study of the VIASKIN Peanut PatchJun 3, 2026
• DBV Technologies planned to present additional Phase 3 VITESSE data on the VIASKIN peanut patch in children aged 4 to 7 and discuss the future of EPIT at AAAAI 2026Feb 11, 2026
• DBV Technologies announces last patient visit completed in VITESSE Phase 3 clinical trial of VIASKIN® peanut patch in peanut allergic children aged 4-7 yearsNov 12, 2025